Clinical Trial

Preliminary Efficacy Analysis of 'λ+α' Double-Tract Reconstruction After Laparoscopic Proximal Gastrectomy

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 15, 2024 (before its estimated December 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The incidence of proximal gastric cancer has increased significantly in recent years. This may be due to weight gain, alcohol consumption, gastroesophageal reflux disease (GERD), and precancerous lesions. With a deeper understanding of the pattern of lymph node metastasis and the emergence of anti-reflux procedures, proximal gastrectomy has gradually received clinical attention. For early-stage upper gastric cancer and esophagogastric combination cancer cases that are expected to have a good prognosis, the ideal surgical procedure should be to preserve the distal stomach to improve the quality of life and to choose a reasonable digestive tract reconstruction method to prevent reflux. The anti-reflux effect of various proximal gastrectomy digestive tract reconstruction methods and the advantages and disadvantages of various surgical procedures are controversial, and the recognized ideal reconstruction method has not yet been established. Therefore, based on the stomach's anatomical features and the intercalated jejunum's anti-reflux mechanism, we propose a true dual-channel anastomosis for GI reconstruction, i.e., the "λ+α dual-channel anastomosis". This study aimed to investigate the efficacy and safety of proximal gastrectomy combined with "λ+α double-channel anastomosis" in the treatment of early gastric cancer.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-06-20.
Status change: Not Yet Recruiting → Recruiting 2024-08-13
Trial Details
NCT Number NCT06475170
Lead Sponsor Northern Jiangsu People's Hospital
Conditions Gastric Cancer, Reflux Esophagitis
Enrollment 60 participants
Start Date 2024-08-01
Primary Completion 2025-12-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-08-15